Summary of univariate survival analyses by pretreatment S-VEGF and S-bFGF in different subgroups of 200 patients with NHL
| . | n . | 5-year survival (%) . | P . |
|---|---|---|---|
| Intermediate and high-grade lymphomas (n = 145) | |||
| Serum VEGF at diagnosis | |||
| < highest quartile | 109 | 55 | <.0035 |
| highest quartile | 36 | 32 | |
| Serum bFGF at diagnosis | |||
| < highest quartile | 109 | 54 | .014 |
| highest quartile | 36 | 34 | |
| Serum VEGF and bFGF at diagnosis | |||
| both < highest quartile | 85 | 57 | <.0001 |
| both highest quartile | 12 | 8 | |
| Low grade lymphomas (n = 47) | |||
| Serum VEGF at diagnosis | |||
| < highest quartile | 35 | 79 | .016 |
| highest quartile | 12 | 39 | |
| Serum bFGF at diagnosis | |||
| < highest quartile | 35 | 74 | .26 |
| highest quartile | 12 | 54 | |
| Serum VEGF and bFGF at diagnosis | |||
| both < highest quartile | 28 | 75 | .0010 |
| both highest quartile | 7 | 14 | |
| Large cell diffuse and immunoblastic lymphomas (n = 78) | |||
| Serum VEGF at diagnosis | |||
| < highest quartile | 58 | 53 | .0095 |
| highest quartile | 20 | 30 | |
| Serum bFGF at diagnosis | |||
| < highest quartile | 58 | 55 | .020 |
| highest quartile | 20 | 25 | |
| Serum VEGF and bFGF at diagnosis | |||
| both < highest quartile | 46 | 57 | <.0001 |
| both highest quartile | 8 | 0 |
| . | n . | 5-year survival (%) . | P . |
|---|---|---|---|
| Intermediate and high-grade lymphomas (n = 145) | |||
| Serum VEGF at diagnosis | |||
| < highest quartile | 109 | 55 | <.0035 |
| highest quartile | 36 | 32 | |
| Serum bFGF at diagnosis | |||
| < highest quartile | 109 | 54 | .014 |
| highest quartile | 36 | 34 | |
| Serum VEGF and bFGF at diagnosis | |||
| both < highest quartile | 85 | 57 | <.0001 |
| both highest quartile | 12 | 8 | |
| Low grade lymphomas (n = 47) | |||
| Serum VEGF at diagnosis | |||
| < highest quartile | 35 | 79 | .016 |
| highest quartile | 12 | 39 | |
| Serum bFGF at diagnosis | |||
| < highest quartile | 35 | 74 | .26 |
| highest quartile | 12 | 54 | |
| Serum VEGF and bFGF at diagnosis | |||
| both < highest quartile | 28 | 75 | .0010 |
| both highest quartile | 7 | 14 | |
| Large cell diffuse and immunoblastic lymphomas (n = 78) | |||
| Serum VEGF at diagnosis | |||
| < highest quartile | 58 | 53 | .0095 |
| highest quartile | 20 | 30 | |
| Serum bFGF at diagnosis | |||
| < highest quartile | 58 | 55 | .020 |
| highest quartile | 20 | 25 | |
| Serum VEGF and bFGF at diagnosis | |||
| both < highest quartile | 46 | 57 | <.0001 |
| both highest quartile | 8 | 0 |
Highest quartiles of S-VEGF and S-bFGF within the respective subgroups were used as cutoff values.